Role of C reactive protein (CRP) in leptin resistance

Current Pharmaceutical Design

Volumn 20, Issue 4, 2014, Pages 609-615

  Hribal, Marta Letizia ^a   Fiorentino, Teresa Vanessa ^a   Sesti, Giorgio ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Cardiovascular disease; CRP; Leptin; Leptin resistance

Indexed keywords

C REACTIVE PROTEIN; LEPTIN; LEPTIN RECEPTOR;

BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GENE LOCUS; GENETIC VARIABILITY; HORMONE ACTION; HORMONE RESISTANCE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MOLECULAR PATHOLOGY; PATHOGENESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; HUMANS; LEPTIN; MODELS, CARDIOVASCULAR; RISK; UP-REGULATION;

EID: 84894065705     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990016     Document Type: Review

References (58)

1. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-32.
2. Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995; 269: 540-3.
3. Chen H, Charlat O, Tartaglia LA, et al. Evidence that the diabetes gene encodes the leptin receptor: Identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996; 84: 491-5.
4. Considine RV, Considine EL, Williams CJ, et al. Evidence against either a premature stop codon or the absence of obese gene mRNA in human obesity. J Clin Invest 1995; 95: 2986-8.
5. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell 1996; 87: 377-89.
6. Zimmet P, Boyko EJ, Collier GR, de Courten M. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann N Y Acad Sci 1999; 892: 25-44.
7. Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol 2008; 52: 1201-10.
8. Bełtowski J. Leptin and the regulation of endothelial function in physiological and pathological conditions. Clin Exp Pharmacol Physiol 2012; 39: 168-78.
9. Blake GJ, Ridker PM. Novel Clinical Markers of Vascular Wall Inflammation. Circ Res 2001; 89: 763-71.
10. Baker RG, Hayden MS, Ghosh S. NF-κB, inflammation, and metabolic disease. Cell Metab 2011; 13: 11-22.
11. Herder C, Baumert J, Zierer A, et al. Immunological and cardiometabolic risk factors in the prediction of type 2 diabetes and coronary events: MONICA/KORA Augsburg case-cohort study. PLoS One 2011; 6: e19852.
12. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. Creactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-34.
13. Perticone F, Maio R, Sciacqua A, et al. Endothelial dysfunction and C-reactive protein are risk factors for diabetes in essential hypertension. Diabetes 2008; 57: 167-71.
14. Yudkin JS Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: association with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from the adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972-8.
15. Yoon SS, Dillon CF, Carroll M, Illoh K, Ostchega Y. Effects of statins on serum inflammatory markers: the U.S. National Health and Nutrition Examination Survey 1999-2004. J Atheroscler Thromb 2010; 17: 1176-82.
16. Cardellini M, Andreozzi F, Laratta E, et al. Plasma interleukin-6 levels are increased in subjects with impaired glucose tolerance but not in those with impaired fasting glucose in a cohort of Italian Caucasians. Diabetes Metab Res Rev 2007; 23: 141-5.
17. Knudsen EC, Seljeflot I, Michael A, et al. Increased levels of CRP and MCP-1 are associated with previously unknown abnormal glucose regulation in patients with acute STEMI: a cohort study. Cardiovasc Diabetol 2010; 9: 47.
18. Temelkova-Kurktschiev T Henkel E, Koehler C, Karrei K, Hanefeld M. Subclinical inflammation in newly detected type II diabetes and impaired glucose tolerance. Diabetologia 2002; 45: 151.
19. Verma S. Wang CH, Li SH et al. A self-fulfilling prophecy: Creactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106: 913-9.
20. Montero I, Orbe J, Varo N. et al. C-reactive protein induces matrix metalloproteinase-1 and-10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol 2006; 47: 1369-78.
21. Hattori Y Matsumura M, Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res 2003; 58: 186-95.
22. D'Alessandris C, Lauro R, Presta I, Sesti G. C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser307 and Ser 612 in L6 myocytes, thereby impairing the insulin signalling pathway that promotes glucose transport. Diabetologia 2007; 50: 840-9.
23. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women. N Engl J Med 2000; 342: 836-43.
24. Singh M, Bedi US, Singh PP, Arora R, Khosla S. Leptin and the clinical cardiovascular risk. Int J Cardiol 2010; 140: 266-71.
25. Reilly MP, Iqbal N, Schutta M, et al. Plasma Leptin Levels Are Associated with Coronary Atherosclerosis in Type 2 Diabetes. J Clin Endocrinol Metab 2004; 89: 3872-8.
26. Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104: 3052-6.
27. Kazumi T, Kawaguchi A, Hirano T, Yoshino G. C-reactive protein in young, apparently healthy men: associations with serum leptin, QTc interval, and high-density lipoprotein-cholesterol. Metabolism 2003; 52: 1113-6.
28. Shamsuzzaman AS, Winnicki M, Wolk R, et al. Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 2004; 109: 2181-5.
29. Ble A, Windham BG, Bandinelli S, et al. Relation of plasma leptin to C-reactive protein in older adults (from the Invecchiare nel Chianti study). Am J Cardiol 2005; 96: 991-5.
30. Viikari LA, Huupponen RK, Viikari JSA, et al. Relationship between Leptin and C-Reactive Protein in Young Finnish Adults. J Clin Endocrinol Metab 2007; 92: 4753-8.
31. Gómez-Ambrosi J, Salvador J, Páramo JA, et al. Involvement of leptin in the association between percentage of body fat and cardiovascular risk factors Clin Biochem 2002; 35: 315-20.
32. van Dielen FMH, van't Veer C, Schols AM, Soeters PB, Buurman WA, Greve JWM. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obesity 2001; 25: 1759-66.
33. Yanagawa T, Taniguchi A, Fukushima M, et al. Leptin, triglycerides, and interleukin 6 are independently associated with Creactive protein in Japanese type 2 diabetic patients 2007; 75: 2-6.
34. Park JS, Cho MH, Nam JS, et al. Visceral adiposity and leptin are independently associated with C-reactive protein in Korean type 2 diabetic patients Acta Diabetol 2010; 47: 113-8.
35. Romero-Corral A, Sierra-Johnson J, Lopez-Jimenez F, et al. Relationships between leptin and C-reactive protein with cardiovascular disease in the adult general population. Nat Clin Pract Cardiovasc Med. 2008; 5: 418-25.
36. Wolk R Berger P, Lennon RJ, Brilakis ES, Johnson BD, Somers VK. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol 2004; 44: 1819-24.
37. Wallace AM McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104: 3052-3056.
38. Martin SS, Qasim AN, Rader DJ, Reilly MP. C-Reactive Protein Modifies the Association of Plasma Leptin With Coronary Calcium in Asymptomatic Overweight Individuals. Obesity 2011; doi: 10.1038/oby.2011.164.
39. Weinhold B, Rüther U. Interleukin-6-dependent and-independent regulation of the human C-reactive protein gene. Biochem J 1997; 327: 425-9.
40. Chen K, Li F, Li J, et al. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med 2006; 4: 426-32.
41. Calabro P, Willerson JT, Yeh ETH. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003; 108: 1930-2.
42. Singh P, Hoffmann M, Wolk R, Shamsuzzaman ASM, Somers K. Leptin Induces C-Reactive Protein Expression in Vascular Endothelial Cells. Arterioscler Thromb Vasc Biol 2007; 27: e302-7.
43. De Rosa S, Cirillo P, Pacileo M, Di Palma V, Paglia A, Chiariello M. Leptin stimulated C-reactive protein production by human coronary artery endothelial cells. J Vasc Res 2009; 46: 609-17.
44. Mackintosh RM, Hirsch J. The effects of leptin administration in non-obese human subjects. Ob Res 2001; 9: 462-9.
45. Hukshorn CJ, Lindeman JHN, Toet KH, et al. Leptin and the Proinflammatory State Associated with Human Obesity. J Clin Endocrinol Metab 2004; 89: 1773-8.
46. Canavan B, Salem RO, Schurgin S, et al. Effects of physiological leptin administration on markers of inflammation, platelet activation, and platelet aggregation during caloric deprivation. J Clin Endocrinol Metab 2005; 90: 5779-85.
47. Hukshorn CJ, van Dielen FM, Buurman WA, Westerterp-Plantenga MS, Campfield LA, Saris WH. The effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects. Int J Obes Relat Metab Disord 2002; 26: 504-509.
48. Farooqi SI, O'Rahilly S. Is leptin an important physiological regulator of CRP? Nat Med 2007; 13: 16-7.
49. Chan JL, Bullen J, Stoyneva V, Depaoli AM, Addy C, Mantzoros CS. Recombinant methionyl human leptin administration to achieve high physiologic or pharmacologic leptin levels does not alter circulating inflammatory marker levels in humans with leptin sufficiency or excess. J Clin Endocrinol Metab 2005; 90: 1618-24.
50. Hutchinson WL, Coll AP, Gallimore JR, Tennent GA, Pepys MB. Is leptin an important physiological regulator of CRP? Nat Med 2007; 13: 17-8.
51. Gertler A, Niv-Spector L, Reicher S. Is leptin an important physiological regulator of CRP? Nat Med 2007; 13: 18-9.
52. Procopio C, Andreozzi F, Laratta E, et al. Leptin-Stimulated Endothelial Nitric-Oxide Synthase via an Adenosine 5'-Monophosphate-Activated Protein Kinase/Akt Signaling Pathway Is Attenuated by Interaction with C-Reactive Protein. Endocrinology 2009; 150: 3584-93.
53. Zhang YY, Gottardo L, Mlynarski W, et al. Genetic variability at the leptin receptor (LEPR) locus is a determinant of plasma fibrinogen and C-reactive protein levels. Atherosclerosis 2007; 191: 121-7.
54. Ridker PM, Pare G, Parker A, et al. Loci related to metabolicsyndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am J Hum Gen 2008; 82: 1185-92.
55. Balducci S, Zanuso S, Nicolucci A, et al. Anti-inflammatory effect of exercise training in subjects with type 2 diabetes and the metabolic syndrome is dependent on exercise modalities and independent of weight loss. Nutr Metab Cardiovasc Dis 2010; 20: 608-17.
56. Rider OJ, Tayal U, Francis JM, et al. The effect of obesity and weight loss on aortic pulse wave velocity as assessed by magnetic resonance imaging. Obesity(Silver Spring) 2010; 18: 2311-6.
57. Pardina E, Ferrer R, Baena-Fustegueras JA, et al. The relationships between IGF-1 and CRP, NO, leptin, and adiponectin during weight loss in the morbidly obese., Obes Surg 2010; 20: 623-32.
58. Brethauer SA, Heneghan HM, Eldar S, et al. Early effects of gastric bypass on endothelial function, inflammation, and cardiovascular risk in obese patients Surg Endosc 2011; 25: 2650-9.